Issues related to End Stage Renal Disease (ESRD) and Chronic Kidney Disease;
H.R. 6860, Restore Protections for Dialysis Patients Act;
H.R. 5027, Chronic Kidney Disease Improvement in Research and Treatment Act of 2023;
Medicare Program; End-Stage Renal Disease Prospective Payment System, Payment for Renal Dialysis Services Furnished to Individuals With Acute Kidney Injury, End-Stage Renal Disease Quality Incentive Program, and End-Stage Renal Disease Treatment Choices Model (11/6/23);
Challenges associated with CMMI Kidney Models;
H.R. 5074, Kidney PATIENT Act of 2023
Expiring healthcare extenders;
H.R. 4366, the Consolidated Appropriations Act, 2024 (P.L. 118-42);
H.R. 2882, the Further Consolidated Appropriations Act, 2024 (P.L. 118-47)
Duration: March 1, 2016
to
present
General Issues: Medicare/Medicaid , Health Issues , Veterans
Spending: about $1,700,000 (But it's complicated. Here's why.)
It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.
Agencies lobbied since 2016: House of Representatives, U.S. Senate, Health Resources & Services Administration (HRSA), Centers For Medicare and Medicaid Services (CMS), White House Office, Office of Management & Budget (OMB)
Related Foreign Entities:
Fresenius Medical Care AG & Co. KGaA (61352 Bad Homburg, GER); contribution to lobbying: $0; ownership 100%
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Lobbyist
Covered positions?
Tracy Spicer Deputy Chief of Staff, Political Director, Legislative Assistant, Special Assistant, Staff Assistant - Sen. Edward M. Kennedy
Elizabeth Barnett Legislative Assistant, Speechwriter, Legislative Correspondent - Sen. Blanche Lincoln; Staff Assistant - Senate Energy and Natural Resources Committee
Amy Tejral n/a
Jordan LaCrosse n/a
Aimee Lewis n/a
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
1st Quarter, 2024
In Q1, Avenue Solutions lobbied for Fresenius Medical Care North America , earning $60,000. The report was filed on April 22.
Original Filing: 301574247.xml
Lobbying Issues
Issues related to End Stage Renal Disease (ESRD) and Chronic Kidney Disease;
H.R. 6860, Restore Protections for Dialysis Patients Act;
H.R. 5027, Chronic Kidney Disease Improvement in Research and Treatment Act of 2023;
Medicare Program; End-Stage Renal Disease Prospective Payment System, Payment for Renal Dialysis Services Furnished to Individuals With Acute Kidney Injury, End-Stage Renal Disease Quality Incentive Program, and End-Stage Renal Disease Treatment Choices Model (11/6/23);
Challenges associated with CMMI Kidney Models;
H.R. 5074, Kidney PATIENT Act of 2023
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Expiring healthcare extenders;
H.R. 4366, the Consolidated Appropriations Act, 2024 (P.L. 118-42);
H.R. 2882, the Further Consolidated Appropriations Act, 2024 (P.L. 118-47)
Agencies Lobbied
U.S. Senate
4th Quarter, 2023
In Q4, Avenue Solutions lobbied for Fresenius Medical Care North America , earning $60,000. The report was filed on Jan. 22.
Original Filing: 301539353.xml
Lobbying Issues
Issues related to End Stage Renal Disease (ESRD) and Chronic Kidney Disease;
H.R. 6860, Restore Protections for Dialysis Patients Act;
Forecast error adjustment to address workforce crisis;
H.R. 5027, Chronic Kidney Disease Improvement in Research and Treatment Act of 2023;
Medicare Program; End-Stage Renal Disease Prospective Payment System, Payment for Renal Dialysis Services Furnished to Individuals With Acute Kidney Injury, End-Stage Renal Disease Quality Incentive Program, and End-Stage Renal Disease Treatment Choices Model (11/6/23);
Challenges associated with CMMI Kidney Models;
H.R. 5074, Kidney PATIENT Act of 2023
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Expiring healthcare extenders
Agencies Lobbied
U.S. Senate
3rd Quarter, 2023
In Q3, Avenue Solutions lobbied for Fresenius Medical Care North America , earning $60,000. The report was filed on Oct. 20, 2023.
Original Filing: 301510977.xml
Lobbying Issues
Issues related to End Stage Renal Disease (ESRD) and Chronic Kidney Disease;
Medicare Secondary Payer;
Forecast error adjustment to address workforce crisis;
H.R. 5027, Chronic Kidney Disease Improvement in Research and Treatment Act of 2023;
CMS-1782-P: Medicare Program; End-Stage Renal Disease Prospective Payment System, Payment for Renal Dialysis Services Furnished to Individuals With Acute Kidney Injury, End-Stage Renal Disease Quality Incentive Program, and End-Stage Renal Disease Treatment Choices Model
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2023
In Q2, Avenue Solutions lobbied for Fresenius Medical Care North America , earning $60,000. The report was filed on July 19, 2023.
Original Filing: 301483957.xml
Lobbying Issues
Issues related to End Stage Renal Disease (ESRD) and Chronic Kidney Disease;
Medicare Secondary Payer;
Forecast error adjustment to address workforce crisis
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2023
In Q1, Avenue Solutions lobbied for Fresenius Medical Care North America , earning $60,000. The report was filed on April 20, 2023.
Original Filing: 301464199.xml
Lobbying Issues
Issues related to End Stage Renal Disease (ESRD) and Chronic Kidney Disease;
Medicare Secondary Payer;
Forecast error adjustment to address workforce crisis;
Adjustment of the Prospective Payment System (PPS) payment rate after the Transitional Drug Add-on Payment Adjustment (TDAPA) period ends for new drugs and biological products CMS determines are within an existing ESRD functional category;
Creation of incentives to adopt innovation for patients enrolled in Medicare Advantage plans
Delay implementation of the ESRD-related drug policy to bring oral phosphate lowering drugs under the Medicare ESRD PPS until the earlier of January 1, 2033 or such time as intravenous options are approved
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2022
In Q4, Avenue Solutions lobbied for Fresenius Medical Care North America , earning $60,000. The report was filed on Jan. 20, 2023.
Original Filing: 301439630.xml
Lobbying Issues
Issues related to End Stage Renal Disease and Chronic Kidney Disease;
End Stage Renal Disease (ESRD) Prospective Payment System (PPS) and utilization of calcimimetic drugs;
S. 1971, Chronic Kidney Disease Improvement in Research and Treatment Act of 2021;
H.R. 4065, To improve the understanding of, and promote access to treatment for, chronic kidney disease, and for other purposes;
Medicare Secondary Payer;
H.R. 7878/S. 4307 Kidney Health Connect Act of 2022;
Calendar Year 2023 End-Stage Renal Disease (ESRD) Prospective Payment System (PPS) Final Rule (CMS-1768-F);
H.R. 8594/S. 4750, Restore Protections for Dialysis Patients Act
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Provider Relief Fund, phase 4 reconsideration;
S. 3799, PREVENT Pandemics Act;
Issues related to the Public Health Emergency;
H.R. 2617, Consolidated Appropriations Act, 2023 - increasing Medicare Physician Fee Schedule payments and extending all Medicare telehealth flexibilities extended in the Consolidated Appropriations Act of 2022 through December 31, 2024
Agencies Lobbied
U.S. Senate
3rd Quarter, 2022
In Q3, Avenue Solutions lobbied for Fresenius Medical Care North America , earning $60,000. The report was filed on Oct. 20, 2022.
Original Filing: 301413182.xml
Lobbying Issues
Issues related to End Stage Renal Disease and Chronic Kidney Disease;
End Stage Renal Disease (ESRD) Prospective Payment System (PPS) and utilization of calcimimetic drugs;
S. 1971, Chronic Kidney Disease Improvement in Research and Treatment Act of 2021;
H.R. 4065, To improve the understanding of, and promote access to treatment for, chronic kidney disease, and for other purposes;
Medicare Secondary Payer;
H.R. 7878/S. 4307 Kidney Health Connect Act of 2022;
Calendar Year 2023 End-Stage Renal Disease (ESRD) Prospective Payment System (PPS) Proposed Rule, issued 6/21/22;
H.R. 8594/S. 4750, Restore Protections for Dialysis Patients Act
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to H.R. 5376, Inflation Reduction Act of 2022 (now PL 117-169) and implementation;
Provider Relief Fund, phase 4 reconsideration;
S. 3799, PREVENT Pandemics Act;
Issues related to the Public Health Emergency;
Issues related to the FY 2023 Presidents Budget
Agencies Lobbied
U.S. Senate
2nd Quarter, 2022
In Q2, Avenue Solutions lobbied for Fresenius Medical Care North America , earning $60,000. The report was filed on July 20, 2022.
Original Filing: 301391973.xml
Lobbying Issues
Issues related to End Stage Renal Disease and Chronic Kidney Disease;
End Stage Renal Disease (ESRD) Prospective Payment System (PPS) and utilization of calcimimetic drugs
S. 1971, Chronic Kidney Disease Improvement in Research and Treatment Act of 2021;
H.R. 4065, To improve the understanding of, and promote access to treatment for, chronic kidney disease, and for other purposes;
Medicare Secondary Payer;
H.R. 7878/S. 4307 Kidney Health Connect Act of 2022;
Calendar Year 2023 End-Stage Renal Disease (ESRD) Prospective Payment System (PPS) Proposed Rule, issued 6/21/22
Agencies Lobbied
U.S. Senate
Lobbying Issues
Monitor possible healthcare policies in upcoming reconciliation package including: making ACA tax credits/subsidies permanent, addressing Medicaid coverage gap, expanding home and community based services, prescription drug reform;
H.R. 5376, Build Back Better Act;
Provider Relief Fund, phase 4 reconsideration;
S.3799, PREVENT Pandemics Act;
Issues related to the Public Health Emergency;
Issues related to the FY 2023 Presidents Budget
Agencies Lobbied
U.S. Senate
1st Quarter, 2022
In Q1, Avenue Solutions lobbied for Fresenius Medical Care North America , earning $60,000. The report was filed on April 20, 2022.
Original Filing: 301370930.xml
Lobbying Issues
Issues related to End Stage Renal Disease and Chronic Kidney Disease;
Implementation of American Rescue Plan Act of 2021 (PL 117-2);
Extension of the Medicare Sequester;
S. 748, Medicare Sequester Relief Act;
Telehealth issues related to COVID-19;
H.R. 1999, To delay and offset the sequester under the Statutory Pay-As-You-Go Act of2010 as a result of the enactment of the American Rescue Plan Act of 2021, and for other purposes;
End Stage Renal Disease (ESRD) Prospective Payment System (PPS) and utilization of calcimimetic drugs
S. 1971, Chronic Kidney Disease Improvement in Research and Treatment Act of 2021;
H.R. 4065, To improve the understanding of, and promote access to treatment for, chronic kidney disease, and for other purposes;
Kildee/Wenstrup draft legislation to expand the ability of renal dialysis facilities to serve as originating sites for Medicare telehealth services
Agencies Lobbied
U.S. Senate
Lobbying Issues
Implementation of American Rescue Plan Act of 2021 (PL 117-2);
Monitor possible healthcare policies in upcoming reconciliation package including: making ACA tax credits/subsidies permanent, addressing Medicaid coverage gap, expanding home and community based services, prescription drug reform;
H.R. 5376, Build Back Better Act;
Provider Relief Fund;
Consolidated Appropriations Act, 2022 (PL 117-103);
S.3799, PREVENT Pandemics Act;
Issues related to the Public Health Emergency;
Supply chain issues related to dialysis facilities, including long haul trucking;
Issues related to backlog of visas for skilled nurses;
H.R. 7007, COVID Supplemental Appropriations Act, 2022;
Issues related to the FY 2023 Presidents Budget
Agencies Lobbied
U.S. Senate
4th Quarter, 2021
In Q4, Avenue Solutions lobbied for Fresenius Medical Care North America , earning $60,000. The report was filed on Jan. 19, 2022.
Original Filing: 301329834.xml
Lobbying Issues
End Stage Renal Disease (ESRD) Treatment Choices Model (ETC Model) Proposed Rule (84 FR 34478, 7/18/19);
Issues related to End Stage Renal Disease and Chronic Kidney Disease;
Implementation of American Rescue Plan Act of 2021 (PL 117-2);
Continued monitoring of Consolidated Appropriations Act, 2021 (PL 116-260);
Extension of the Medicare Sequester;
S. 748, Medicare Sequester Relief Act;
Telehealth Expansion Act;
Telehealth issues related to COVID-19;
S. 150/H.R. 2166, Ensuring Parity in MA for Audio-Only Telehealth Act of 2021;
Medicare ESRD payment and use of calcimimetic drugs;
Issues related to evaluation and management (E&M) cuts contained in the CY2021 Medicare Physician Fee Schedule (MPFS) Proposed Rule;
H.R. 1999, To delay and offset the sequester under the Statutory Pay-As-You-Go Act of2010 as a result of the enactment of the American Rescue Plan Act of 2021, and for other purposes;
PL-117-71 Protecting Medicare and American Families from Sequester Cuts Act - specifically: 6 months relief from 2% Medicare sequester, 4% statutory Pay-As-You-Go Act, 1 year relief of physician conversion factor cuts, 1 year delay of clinical lab (PAMA) cuts, delay of radiation oncology demo
Agencies Lobbied
U.S. Senate
Lobbying Issues
Implementation of American Rescue Plan Act of 2021 (PL 117-2);
Continued monitoring of Consolidated Appropriations Act, 2021 (PL 116-260);
Vaccine distribution for dialysis facilities;
Monitor possible healthcare policies in upcoming reconciliation package including: making ACA tax credits/subsidies permanent, adding Medicare enhancements/supplemental benefits (hearing, dental, vision), addressing Medicaid coverage gap, expanding home and community based services, prescription drug reform;
H.R. 5376, Build Back Better Act;
Provider Relief Fund;
PL 117-58 - Infrastructure Investment and Jobs Act (BIF) - issues related to rebate rule delay, repurposed Provider Relief Funds, Medicare savings from single source vial size drug policy and extension of mandatory sequester)
Agencies Lobbied
U.S. Senate
3rd Quarter, 2021
In Q3, Avenue Solutions lobbied for Fresenius Medical Care North America , earning $60,000. The report was filed on Oct. 20, 2021.
Original Filing: 301313519.xml
Lobbying Issues
End Stage Renal Disease (ESRD) Treatment Choices Model (ETC Model) Proposed Rule (84 FR 34478, 7/18/19);
Issues related to End Stage Renal Disease and Chronic Kidney Disease;
Implementation of American Rescue Plan Act of 2021 (PL 117-2);
Continued monitoring of Consolidated Appropriations Act, 2021 (PL 116-260);
Extension of the Medicare Sequester;
H.R. 1868, To prevent across-the-board direct spending cuts, and for other purposes;
S. 748, Medicare Sequester Relief Act;
Telehealth Expansion Act;
Telehealth issues related to COVID-19;
S. 150/H.R. 2166, Ensuring Parity in MA for Audio-Only Telehealth Act of 2021;
Medicare ESRD payment and use of calcimimetic drugs;
Issues related to evaluation and management (E&M) cuts contained in the CY2021 Medicare Physician Fee Schedule (MPFS) Proposed Rule;
H.R. 1999, To delay and offset the sequester under the Statutory Pay-As-You-Go Act of 2010 as a result of the enactment of the American Rescue Plan Act of 2021, and for other purposes
Agencies Lobbied
U.S. Senate
Lobbying Issues
Implementation of American Rescue Plan Act of 2021 (PL 117-2);
Continued monitoring of Consolidated Appropriations Act, 2021 (PL 116-260);
Vaccine distribution for dialysis facilities;
Monitor possible healthcare policies in upcoming reconciliation package including: making ACA tax credits/subsidies permanent, adding Medicare enhancements/supplemental benefits (hearing, dental, vision), addressing Medicaid coverage gap, expanding home and community based services, prescription drug reform;
S. 2210, Better Care Better Jobs Act;
H.R. 5376, Build Back Better Act
Agencies Lobbied
U.S. Senate
2nd Quarter, 2021
In Q2, Avenue Solutions lobbied for Fresenius Medical Care North America , earning $60,000. The report was filed on July 20, 2021.
Original Filing: 301289591.xml
Lobbying Issues
End Stage Renal Disease (ESRD) Treatment Choices Model (ETC Model) Proposed Rule (84 FR 34478, 7/18/19);
Issues related to End Stage Renal Disease and Chronic Kidney Disease;
Implementation of American Rescue Plan Act of 2021 (PL 117-2);
Continued monitoring of Consolidated Appropriations Act, 2021 (PL 116-260);
Extension of the Medicare Sequester;
H.R. 1868, To prevent across-the-board direct spending cuts, and for other purposes;
S. 748, Medicare Sequester Relief Act;
Telehealth Expansion Act;
Telehealth issues related to COVID-19;
S. 150/H.R. 2166, Ensuring Parity in MA for Audio-Only Telehealth Act of 2021;
Medicare ESRD payment and use of calcimimetic drugs
Agencies Lobbied
U.S. Senate
Lobbying Issues
Implementation of American Rescue Plan Act of 2021 (PL 117-2);
Continued monitoring of Consolidated Appropriations Act, 2021 (PL 116-260);
Vaccine distribution for dialysis facilities;
Possible healthcare policies in upcoming reconciliation package including: making ACA tax credits/subsidies permanent, adding Medicare enhancements/supplemental benefits (hearing, dental, vision), addressing Medicaid coverage gap, expanding home and community based services;
Senate HELP and Energy & Commerce Public Option RFI;
S. 2210, Better Care Better Jobs Act
Agencies Lobbied
U.S. Senate
1st Quarter, 2021
In Q1, Avenue Solutions lobbied for Fresenius Medical Care North America , earning $60,000. The report was filed on April 20, 2021.
Original Filing: 301261671.xml
Lobbying Issues
End Stage Renal Disease (ESRD) Treatment Choices Model (ETC Model) Proposed Rule (84 FR 34478, 7/18/19);
Issues related to End Stage Renal Disease and Chronic Kidney Disease;
H.R.1319, American Rescue Plan Act of 2021 (PL 117-2);
Continued monitoring of Consolidated Appropriations Act, 2021 (PL 116-260);
Extension of the Medicare Sequester;
H.R. 1868, To prevent across-the-board direct spending cuts, and for other purposes;
S. 748, Medicare Sequester Relief Act;
Telehealth Expansion Act;
Telehealth issues related to COVID-19;
S. 150/H.R. 2166, Ensuring Parity in MA for Audio-Only Telehealth Act of 2021
Agencies Lobbied
U.S. Senate
Lobbying Issues
Continued monitoring of implementation of Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 (PL 116-123);
Continued monitoring of implementation of Families First Coronavirus Response Act (PL 116-127);
Continued monitoring of implementation of CARES Act (PL 116-136) - proposals related to physician and provider relief;
Continued monitoring of Consolidated Appropriations Act, 2021 (PL 116-260);
Vaccine distribution for dialysis facilities
Agencies Lobbied
U.S. Senate
4th Quarter, 2020
In Q4, Avenue Solutions lobbied for Fresenius Medical Care North America , earning $50,000. The report was filed on Jan. 21, 2021.
Original Filing: 301243723.xml
Lobbying Issues
End Stage Renal Disease (ESRD) Treatment Choices Model (ETC Model) Proposed Rule (84 FR 34478, 7/18/19);
Issues related to End Stage Renal Disease and Chronic Kidney Disease;
Executive Order on Advancing American Kidney Health (July 10, 2019);
Monitor Contract Year 2021 Policy and Technical Changes to the Medicare Advantage Program, Medicare Prescription Drug Benefit Program, and Medicare Cost Plan Program Final Rule;
H.R. 8337, Continuing Appropriations Act, 2021 and Other Extensions Act; Public Law 116-159;
Issues related to evaluation and management (E&M) cuts contained in the CY2021 Medicare Physician Fee Schedule (MPFS) Proposed Rule;
Extension of the Medicare Sequester
Agencies Lobbied
U.S. Senate
Lobbying Issues
Continued monitoring of implementation of Public Law 116-123, Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020;
Continued monitoring of implementation of Public Law 116-127, Families First Coronavirus Response Act;
Continued monitoring of implementation of Public Law 116-136, CARES Act - proposals related to physician and provider relief;
H.R. 6800, The Heroes Act (particularly childcare provisions)
H.R. 925, The Heroes Act (particularly childcare provisions)
Telehealth issues related to COVID-19;
H.R. 133, Consolidated Appropriations Act, 2021 (Public Law 116-260)
Agencies Lobbied
U.S. Senate
3rd Quarter, 2020
In Q3, Avenue Solutions lobbied for Fresenius Medical Care North America , earning $50,000. The report was filed on Oct. 20, 2020.
Original Filing: 301222799.xml
Lobbying Issues
End Stage Renal Disease (ESRD) Treatment Choices Model (ETC Model) Proposed Rule (84 FR 34478, 7/18/19);
Issues related to End Stage Renal Disease and Chronic Kidney Disease;
Executive Order on Advancing American Kidney Health (July 10, 2019);
Monitor Contract Year 2021 Policy and Technical Changes to the Medicare Advantage Program, Medicare Prescription Drug Benefit Program, and Medicare Cost Plan Program Final Rule;
H.R. 8337, Continuing Appropriations Act, 2021 and Other Extensions Act; Public Law 116-159
Agencies Lobbied
U.S. Senate
Lobbying Issues
Continued monitoring of implementation of Public Law 116-123, Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020;
Continued monitoring of implementation of Public Law 116-127, Families First Coronavirus Response Act;
Continued monitoring of implementation of Public Law 116-136, CARES Act - proposals related to physician and provider relief;
H.R. 6800, The Heroes Act (particularly childcare provisions)
H.R. 925, The Heroes Act (particularly childcare provisions)
Telehealth issues related to COVID-19
Agencies Lobbied
U.S. Senate
2nd Quarter, 2020
In Q2, Avenue Solutions lobbied for Fresenius Medical Care North America , earning $50,000. The report was filed on July 20, 2020.
Original Filing: 301201261.xml
Lobbying Issues
End Stage Renal Disease (ESRD) Treatment Choices Model (ETC Model) Proposed Rule (84 FR 34478, 7/18/19);
Issues related to End Stage Renal Disease and Chronic Kidney Disease;
Executive Order on Advancing American Kidney Health (July 10, 2019);
Monitor Contract Year 2021 Policy and Technical Changes to the Medicare Advantage Program, Medicare Prescription Drug Benefit Program, and Medicare Cost Plan Program Final Rule
Agencies Lobbied
U.S. Senate
Lobbying Issues
Continued monitoring of implementation of Public Law 116-123, Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020;
Continued monitoring of implementation of Public Law 116-127, Families First Coronavirus Response Act;
Continued monitoring of implementation of Public Law 116-136, CARES Act - proposals related to physician and provider relief;
H.R. 6800 - HEROES Act;
Telehealth issues related to COVID-19
Agencies Lobbied
U.S. Senate
1st Quarter, 2020
In Q1, Avenue Solutions lobbied for Fresenius Medical Care North America , earning $50,000. The report was filed on April 17, 2020.
Original Filing: 301170080.xml
Lobbying Issues
End Stage Renal Disease (ESRD) Treatment Choices Model (ETC Model) Proposed Rule (84 FR 34478, 7/18/19);
Issues related to End Stage Renal Disease and Chronic Kidney Disease;
Executive Order on Advancing American Kidney Health (July 10, 2019)
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R. 748 (Public Law 116-136), CARES Act - issues related to childcare for essential health workers
Agencies Lobbied
U.S. Senate
4th Quarter, 2019
In Q4, Avenue Solutions lobbied for Fresenius Medical Care North America , earning $50,000. The report was filed on Jan. 18, 2020.
Original Filing: 301120910.xml
Lobbying Issues
End Stage Renal Disease (ESRD) Treatment Choices Model (ETC Model) Proposed Rule (84 FR 34478, 7/18/19);
Issues related to End Stage Renal Disease and Chronic Kidney Disease;
Executive Order on Advancing American Kidney Health (July 10, 2019)
Agencies Lobbied
U.S. Senate
3rd Quarter, 2019
In Q3, Avenue Solutions lobbied for Fresenius Medical Care North America , earning $50,000. The report was filed on Oct. 17, 2019.
Original Filing: 301068896.xml
Lobbying Issues
End Stage Renal Disease (ESRD) Treatment Choices Model (ETC Model) Proposed Rule (84 FR 34478, 7/18/19);
Issues related to End Stage Renal Disease and Chronic Kidney Disease;
Executive Order on Advancing American Kidney Health (July 10, 2019)
Agencies Lobbied
U.S. Senate
2nd Quarter, 2019
In Q2, Avenue Solutions lobbied for Fresenius Medical Care North America , earning $50,000. The report was filed on July 19, 2019.
Original Filing: 301052645.xml
Lobbying Issues
Vascular access reimbursement (2019 ASC Proposed Rule);
End-Stage Renal Disease Seamless Care Organization (ESCO) Model methodology;
S. 988, Improving Transparency and Accuracy in Medicare Part D Spending Act
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to End Stage Renal Disease and Chronic Kidney Disease
Agencies Lobbied
U.S. Senate
1st Quarter, 2019
In Q1, Avenue Solutions lobbied for Fresenius Medical Care North America , earning $50,000. The report was filed on April 19, 2019.
Original Filing: 301031106.xml
Lobbying Issues
Vascular access reimbursement (2019 ASC Proposed Rule);
End-Stage Renal Disease Seamless Care Organization (ESCO) Model methodology
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to End Stage Renal Disease and Chronic Kidney Disease
Agencies Lobbied
U.S. Senate
4th Quarter, 2018
In Q4, Avenue Solutions lobbied for Fresenius Medical Care North America , earning $50,000. The report was filed on Jan. 21, 2019.
Original Filing: 301012088.xml
Lobbying Issues
Vascular access reimbursement (2019 ASC Proposed Rule);
End-Stage Renal Disease Seamless Care Organization (ESCO) Model methodology
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to opioids policies and offsets;
H.R. 6, Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities Act (SUPPORT for Patients and Communities Act);
S. 3120, Helping to End Addiction and Lessen Substance Use Disorders Act of 2018 (HEAL Act of 2018);
S. 2680, Opioid Crisis Response Act of 2018
Agencies Lobbied
U.S. Senate
3rd Quarter, 2018
In Q3, Avenue Solutions lobbied for Fresenius Medical Care North America , earning $50,000. The report was filed on Oct. 19, 2018.
Original Filing: 300990649.xml
Lobbying Issues
H.R. 4143/S. 2065, Dialysis PATIENTS Demonstration Act of 2017;
Vascular access reimbursement (2019 ASC Proposed Rule)
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to opioids policies and offsets;
H.R. 6, Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities Act (SUPPORT for Patients and Communities Act);
S. 3120, Helping to End Addiction and Lessen Substance Use Disorders Act of 2018 (HEAL Act of 2018);
S. 2680, Opioid Crisis Response Act of 2018;
Agencies Lobbied
U.S. Senate
Agencies Lobbied
U.S. Senate
2nd Quarter, 2018
In Q2, Avenue Solutions lobbied for Fresenius Medical Care North America , earning $50,000. The report was filed on July 19, 2018.
Original Filing: 300970565.xml
Lobbying Issues
H.R. 4143/S. 2065, Dialysis PATIENTS Demonstration Act of 2017
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to opioids policies and offsets;
H.R. 6, Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities Act (SUPPORT for Patients and Communities Act);
S. 3120, Helping to End Addiction and Lessen Substance Use Disorders Act of 2018 (HEAL Act of 2018);
S. 2680, Opioid Crisis Response Act of 2018;
Agencies Lobbied
U.S. Senate
1st Quarter, 2018
In Q1, Avenue Solutions lobbied for Fresenius Medical Care North America , earning $50,000. The report was filed on April 19, 2018.
Original Filing: 300951182.xml
Lobbying Issues
Bundled Payments for Care Improvement (BPCI) program;
SNP reauthorization;
Medicare extenders;
S. 870, CHRONIC Care Act of 2017;
Issues related to chronic kidney disease and ESRD;
H.R. 3178, Medicare Part B Improvement Act of 2017;
H.R. 4143/S. 2065, Dialysis PATIENTS Demonstration Act of 2017;
Calcimimetics change to bundle payment
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to healthcare discussions/offsets for budget deal and healthcare extenders;
H.R. 1892 / PL 115-123, Bipartisan Budget Act of 2018;
H.R. 1625 / PL 115-141, Omnibus/Consolidated Appropriations Act of 2018
Agencies Lobbied
U.S. Senate
4th Quarter, 2017
In Q4, Avenue Solutions lobbied for Fresenius Medical Care North America , earning $50,000. The report was filed on Jan. 22, 2018.
Original Filing: 300936357.xml
Lobbying Issues
Bundled Payments for Care Improvement (BPCI) program;
SNP reauthorization;
Medicare extenders;
S. 870, CHRONIC Care Act of 2017;
Issues related to chronic kidney disease and ESRD;
H.R. 3178, Medicare Part B Improvement Act of 2017;
H.R. 4143/S. 2065, Dialysis PATIENTS Demonstration Act of 2017;
Calcimimetics change to bundle payment
Agencies Lobbied
U.S. Senate
Lobbying Issues
Hurricane/disaster relief and impact on healthcare services and supplies in Texas, Florida and Puerto Rico
Agencies Lobbied
U.S. Senate
3rd Quarter, 2017
In Q3, Avenue Solutions lobbied for Fresenius Medical Care North America , earning $50,000. The report was filed on Oct. 17, 2017.
Original Filing: 300905448.xml
Lobbying Issues
Bundled Payments for Care Improvement (BPCI) program;
SNP reauthorization;
Medicare extenders;
S. 870, CHRONIC Care Act of 2017;
Issues related to chronic kidney disease and ESRD;
H.R. 3178, Medicare Part B Improvement Act of 2017
Agencies Lobbied
U.S. Senate
2nd Quarter, 2017
In Q2, Avenue Solutions lobbied for Fresenius Medical Care North America , earning $50,000. The report was filed on July 19, 2017.
Original Filing: 300888608.xml
Lobbying Issues
Bundled Payments for Care Improvement (BPCI) program;
S. 413, Improving Transparency & Accuracy in Medicare Part D Spending Act;
SNP reauthorization;
Medicare extenders discussion;
S. 870, CHRONIC Care Act of 2017;
Issues related to chronic kidney disease & ESRD;
Issues related to legislation pending before the California state legislature that would change staffing requirements at dialysis clinics
Agencies Lobbied
U.S. Senate
1st Quarter, 2017
In Q1, Avenue Solutions lobbied for Fresenius Medical Care North America , earning $50,000. The report was filed on April 20, 2017.
Original Filing: 300874814.xml
Lobbying Issues
Bundled Payments for Care Improvement (BPCI) program;
S. 413 Improving Transparency & Accuracy in Medicare Part D Spending Act
4th Quarter, 2016
In Q4, Avenue Solutions lobbied for Fresenius Medical Care North America , earning $50,000. The report was filed on Jan. 23, 2017.
Original Filing: 300856434.xml
Lobbying Issues
Bundled Payments for Care Improvement (BPCI) program
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2016
In Q3, Avenue Solutions lobbied for Fresenius Medical Care North America , earning $30,000. The report was filed on Oct. 20, 2016.
Original Filing: 300837199.xml
Lobbying Issues
Bundled Payments for Care Improvement (BPCI) program
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2016
In Q2, Avenue Solutions lobbied for Fresenius Medical Care North America , earning $30,000. The report was filed on July 19, 2016.
Original Filing: 300814367.xml
Lobbying Issues
Bundled Payments for Care Improvement (BPCI) program
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2016
In Q1, Avenue Solutions did no lobbying for Fresenius Medical Care North America . The report was filed on April 20, 2016.
Original Filing: 300799952.xml
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate
Searching...